Recent Company News

• 02:50 AM ET Aug 06, 2026
  

  Santen Pharmaceutical reports Q1 net income attributable ¥7.19B vs FactSet ¥7.83B [3 est, ¥6.60-9.52B] (¥1876.0000, 0)

• 05:57 AM ET Aug 03, 2026
  

  Santen Pharmaceutical releases 2026 sustainability report (¥1869.0000, 0)

• 02:13 PM ET Jul 13, 2026
  

  Santen and KYORIN announce joint marketing agreement in Japan for Alesion Eyelid Cream 0.5% (¥2151.0000, 0)

• 09:24 AM ET Jul 13, 2026
  

  Sydnexis (private) announces FDA Adcom to review NDA for SYD-101; date to be determined

• 11:11 PM ET Jul 02, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (64 total)

• 10:51 PM ET Jun 28, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (58 total)

• 01:02 PM ET Jun 26, 2026
  

  Santen Pharmaceutical releases CGR report (¥2128.5000, 0)

• 10:39 PM ET Jun 25, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (67 total)

• 10:43 PM ET Jun 24, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (50 total)

• 04:15 AM ET Jun 19, 2026
  

  Santen Pharmaceutical obtains Japan production and marketing approval for Rhopressa Ophthalmic Solution 0.02% (¥1874.0000, 0)